{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T08:42:40Z","timestamp":1771058560048,"version":"3.50.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Novartis Pharma SAS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-025-01557-7","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T21:33:32Z","timestamp":1742420012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Credibility assessment of a mechanistic model of atherosclerosis to predict cardiovascular outcomes under lipid-lowering therapy"],"prefix":"10.1038","volume":"8","author":[{"given":"Yishu","family":"Wang","sequence":"first","affiliation":[]},{"given":"Eulalie","family":"Courcelles","sequence":"additional","affiliation":[]},{"given":"Emmanuel","family":"Peyronnet","sequence":"additional","affiliation":[]},{"given":"Sol\u00e8ne","family":"Porte","sequence":"additional","affiliation":[]},{"given":"Aliz\u00e9e","family":"Diatchenko","sequence":"additional","affiliation":[]},{"given":"Evgueni","family":"Jacob","sequence":"additional","affiliation":[]},{"given":"Denis","family":"Angoulvant","sequence":"additional","affiliation":[]},{"given":"Pierre","family":"Amarenco","sequence":"additional","affiliation":[]},{"given":"Franck","family":"Boccara","sequence":"additional","affiliation":[]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[]},{"given":"Guillaume","family":"Mah\u00e9","sequence":"additional","affiliation":[]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[]},{"given":"Alexandre","family":"Bastien","sequence":"additional","affiliation":[]},{"given":"Lolita","family":"Portal","sequence":"additional","affiliation":[]},{"given":"Jean-Pierre","family":"Boissel","sequence":"additional","affiliation":[]},{"given":"Sol\u00e8ne","family":"Granjeon-Noriot","sequence":"additional","affiliation":[]},{"given":"Emmanuelle","family":"Bechet","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"1557_CR1","doi-asserted-by":"crossref","unstructured":"Libby, P. et al. Atherosclerosis. Nat. Rev. Dis. Prim. 5, 56 (2019).","DOI":"10.1038\/s41572-019-0106-z"},{"key":"1557_CR2","unstructured":"WHO. Cardiovascular diseases (CVDs). (2021) https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)."},{"key":"1557_CR3","doi-asserted-by":"crossref","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1204\u20131222 (2020).","DOI":"10.1016\/S0140-6736(20)30925-9"},{"key":"1557_CR4","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference, B. A. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Hear. J. 38, 2459\u20132472 (2017).","journal-title":"Eur. Hear. J."},{"key":"1557_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s44161-021-00009-1","volume":"1","author":"S Koplev","year":"2022","unstructured":"Koplev, S. et al. A mechanistic framework for cardiometabolic and coronary artery diseases. Nat. Cardiovasc. Res. 1, 85\u2013100 (2022).","journal-title":"Nat. Cardiovasc. Res."},{"key":"1557_CR6","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.3390\/ijms23063346","volume":"23","author":"S Jebari-Benslaiman","year":"2022","unstructured":"Jebari-Benslaiman, S. et al. Pathophysiology of Atherosclerosis. Int. J. Mol. Sci. 23, 3346 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1557_CR7","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/hc0902.104353","volume":"105","author":"P Libby","year":"2002","unstructured":"Libby, P., Ridker, P. M. & Maseri, A. Inflammation and Atherosclerosis. Circulation 105, 1135\u20131143 (2002).","journal-title":"Circulation"},{"key":"1557_CR8","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy, S. M. et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139, e1082\u2013e1143 (2019).","journal-title":"Circulation"},{"key":"1557_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach, F. et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Hear. J. 41, 111\u2013188 (2020).","journal-title":"Eur. Hear. J."},{"key":"1557_CR10","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/bib\/bby043","volume":"20","author":"F Pappalardo","year":"2019","unstructured":"Pappalardo, F., Russo, G., Tshinanu, F. M. & Viceconti, M. In silico clinical trials: concepts and early adoptions. Brief. Bioinform. 20, 1699\u20131708 (2019).","journal-title":"Brief. Bioinform."},{"key":"1557_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-6-130","volume":"6","author":"MTM Auley","year":"2012","unstructured":"Auley, M. T. M., Wilkinson, D. J., Jones, J. J. & Kirkwood, T. B. A whole-body mathematical model of cholesterol metabolism and its age-associated dysregulation. BMC Syst. Biol. 6, 130 (2012).","journal-title":"BMC Syst. Biol."},{"key":"1557_CR12","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1194\/jlr.M031930","volume":"53","author":"NCA Pas","year":"2012","unstructured":"Pas, N. C. A., van de, Woutersen, R. A., Ommen, B., van, Rietjens, I. M. C. M. & Graaf, A. Ade A physiologically based in silico kinetic model predicting plasma cholesterol concentrations in humans[S]. J. Lipid Res. 53, 2734\u20132746 (2012).","journal-title":"J. Lipid Res."},{"key":"1557_CR13","doi-asserted-by":"publisher","first-page":"e1003509","DOI":"10.1371\/journal.pcbi.1003509","volume":"10","author":"J Lu","year":"2014","unstructured":"Lu, J., H\u00fcbner, K., Nanjee, M. N., Brinton, E. A. & Mazer, N. A. An In-Silico Model of Lipoprotein Metabolism and Kinetics for the Evaluation of Targets and Biomarkers in the Reverse Cholesterol Transport Pathway. PLoS Comput. Biol. 10, e1003509 (2014).","journal-title":"PLoS Comput. Biol."},{"key":"1557_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.biosystems.2016.05.001","volume":"145","author":"AE Morgan","year":"2016","unstructured":"Morgan, A. E., Mooney, K. M., Wilkinson, S. J., Pickles, N. A. & Auley, M. T. M. Mathematically modelling the dynamics of cholesterol metabolism and ageing. Biosystems 145, 19\u201332 (2016).","journal-title":"Biosystems"},{"key":"1557_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/pr10010155","volume":"10","author":"F Zhang","year":"2022","unstructured":"Zhang, F., Macshane, B., Searcy, R. & Huang, Z. Mathematical Models for Cholesterol Metabolism and Transport. Processes 10, 155 (2022).","journal-title":"Processes"},{"key":"1557_CR16","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1194\/jlr.M092486","volume":"60","author":"V Sokolov","year":"2019","unstructured":"Sokolov, V. et al. Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia[S]. J. Lipid Res. 60, 1610\u20131621 (2019).","journal-title":"J. Lipid Res."},{"key":"1557_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/psp.2014.47","volume":"3","author":"K Gadkar","year":"2014","unstructured":"Gadkar, K. et al. A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations. CPT Pharmacomet. Syst. Pharmacol. 3, 1\u20139 (2014).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"1557_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/cpt.2774","volume":"113","author":"NH Gosselin","year":"2023","unstructured":"Gosselin, N. H. et al. Translational Population-Pharmacodynamic Modeling of a Novel Long-Acting siRNA Therapy, Inclisiran, for the Treatment of Hypercholesterolemia. Clin. Pharmacol. Ther. 113, 328\u2013338 (2023).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1557_CR19","doi-asserted-by":"publisher","first-page":"117762501771094","DOI":"10.1177\/1177625017710941","volume":"11","author":"JE Ming","year":"2017","unstructured":"Ming, J. E. et al. A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics. Gene Regul. Syst. Biol. 11, 1177625017710941 (2017).","journal-title":"Gene Regul. Syst. Biol."},{"key":"1557_CR20","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1093\/bioinformatics\/bty980","volume":"35","author":"A Parton","year":"2019","unstructured":"Parton, A., McGilligan, V., Chemaly, M., O\u2019Kane, M. & Watterson, S. New models of atherosclerosis and multi-drug therapeutic interventions. Bioinformatics 35, 2449\u20132457 (2019).","journal-title":"Bioinformatics"},{"key":"1557_CR21","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1161\/ATVBAHA.121.315969","volume":"41","author":"AJ Buckler","year":"2021","unstructured":"Buckler, A. J. et al. Virtual Transcriptomics: Noninvasive Phenotyping of Atherosclerosis by Decoding Plaque Biology From Computed Tomography Angiography Imaging. Arter., Thromb. Vasc. Biol. 41, 1738\u20131750 (2021).","journal-title":"Arter., Thromb. Vasc. Biol."},{"key":"1557_CR22","doi-asserted-by":"publisher","first-page":"106364","DOI":"10.1016\/j.compbiomed.2022.106364","volume":"152","author":"AJ Buckler","year":"2023","unstructured":"Buckler, A. J. et al. In silico model of atherosclerosis with individual patient calibration to enable precision medicine for cardiovascular disease. Comput. Biol. Med. 152, 106364 (2023).","journal-title":"Comput. Biol. Med."},{"key":"1557_CR23","doi-asserted-by":"publisher","unstructured":"Angoulvant, D. et al. In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programme. Eur. J. Prev. Cardiol. zwae254 https:\/\/doi.org\/10.1093\/eurjpc\/zwae254 (2024).","DOI":"10.1093\/eurjpc\/zwae254"},{"key":"1557_CR24","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray, K. K. et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N. Engl. J. Med. 382, 1507\u20131519 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1557_CR25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.7150\/ijbs.5.474","volume":"5","author":"TF Daniels","year":"2009","unstructured":"Daniels, T. F., Killinger, K. M., Michal, J. J., Wright, R. W. Jr. & Jiang, Z. Lipoproteins, cholesterol homeostasis and cardiac health. Int. J. Biol. Sci. 5, 474\u2013488 (2009).","journal-title":"Int. J. Biol. Sci."},{"key":"1557_CR26","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1194\/jlr.R067314","volume":"57","author":"K Schmidt","year":"2016","unstructured":"Schmidt, K., Noureen, A., Kronenberg, F. & Utermann, G. Structure, function, and genetics of lipoprotein (a). J. Lipid Res. 57, 1339\u20131359 (2016).","journal-title":"J. Lipid Res."},{"key":"1557_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00395-015-0463-z","volume":"110","author":"R Schulz","year":"2015","unstructured":"Schulz, R., Schl\u00fcter, K.-D. & Laufs, U. Molecular and cellular function of the proprotein convertase subtilisin\/kexin type 9 (PCSK9). Basic Res. Cardiol. 110, 4 (2015).","journal-title":"Basic Res. Cardiol."},{"key":"1557_CR28","unstructured":"Linton, M. F. et al. The Role of Lipids and Lipoproteins in Atherosclerosis. [Updated 2019 Jan 3]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK343489\/"},{"key":"1557_CR29","doi-asserted-by":"publisher","unstructured":"Wengrofsky, P., Lee, J. & Makaryus, A. N. Dyslipidemia and Its Role in the Pathogenesis of Atherosclerotic Cardiovascular Disease: Implications for Evaluation and Targets for Treatment of Dyslipidemia Based on Recent Guidelines. Dyslipidemia & IntechOpen. https:\/\/doi.org\/10.5772\/intechopen.85772 (2019).","DOI":"10.5772\/intechopen.85772"},{"key":"1557_CR30","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.cell.2022.04.004","volume":"185","author":"JLM Bj\u00f6rkegren","year":"2022","unstructured":"Bj\u00f6rkegren, J. L. M. & Lusis, A. J. Atherosclerosis: Recent developments. Cell 185, 1630\u20131645 (2022).","journal-title":"Cell"},{"key":"1557_CR31","unstructured":"Grundy, S. M. & Feingold, K. R. Guidelines for the Management of High Blood Cholesterol. [Updated 2022 May 28]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK305897\/"},{"key":"1557_CR32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.amjmed.2012.01.014","volume":"125","author":"PWF Wilson","year":"2012","unstructured":"Wilson, P. W. F. et al. An International Model to Predict Recurrent Cardiovascular Disease. Am. J. Med. 125, 695\u2013703.e1 (2012).","journal-title":"Am. J. Med."},{"key":"1557_CR33","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine, M. S. et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N. Engl. J. Med. 376, 1713\u20131722 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1557_CR34","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"Bonaca, M. P. et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. Circulation 137, 338\u2013350 (2018).","journal-title":"Circulation"},{"key":"1557_CR35","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","volume":"73","author":"DM Charytan","year":"2019","unstructured":"Charytan, D. M. et al. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. J. Am. Coll. Cardiol. 73, 2961\u20132970 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1557_CR36","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","volume":"146","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue, M. L. et al. Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease. Circulation 146, 1109\u20131119 (2022).","journal-title":"Circulation"},{"key":"1557_CR37","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz, G. G. et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N. Engl. J. Med. 379, 2097\u20132107 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1557_CR38","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1093\/eurheartj\/ehz809","volume":"41","author":"PR Sinnaeve","year":"2020","unstructured":"Sinnaeve, P. R. et al. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. Eur. Hear. J. 41, 2248\u20132258 (2020).","journal-title":"Eur. Hear. J."},{"key":"1557_CR39","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/S0735-1097(20)32481-5","volume":"75","author":"V Bittner","year":"2020","unstructured":"Bittner, V. et al. ALIROCUMAB AND CARDIOVASCULAR OUTCOMES IN WOMEN AFTER AN ACUTE CORONARY SYNDROME: AN ODYSSEY. OUTCOMES TRIAL Analysis. J. Am. Coll. Cardiol. 75, 1854 (2020).","journal-title":"OUTCOMES TRIAL Analysis. J. Am. Coll. Cardiol."},{"key":"1557_CR40","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","volume":"7","author":"KK Ray","year":"2019","unstructured":"Ray, K. K. et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 7, 618\u2013628 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1557_CR41","doi-asserted-by":"crossref","unstructured":"Tu\u00f1\u00f3n, J. et al. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. Eur. Hear. J. 41, 4114\u20134123 (2020).","DOI":"10.1093\/eurheartj\/ehaa498"},{"key":"1557_CR42","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","volume":"74","author":"JW Jukema","year":"2019","unstructured":"Jukema, J. W. et al. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial. J. Am. Coll. Cardiol. 74, 1167\u20131176 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1557_CR43","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","volume":"141","author":"GG Schwartz","year":"2020","unstructured":"Schwartz, G. G. et al. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of a Randomized Clinical Trial. Circulation 141, 1608\u20131617 (2020).","journal-title":"Circulation"},{"key":"1557_CR44","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon, C. P. et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N. Engl. J. Med. 372, 2387\u20132397 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1557_CR45","doi-asserted-by":"publisher","first-page":"20130866","DOI":"10.1098\/rsif.2013.0866","volume":"11","author":"M Cilla","year":"2014","unstructured":"Cilla, M., Pe\u00f1a, E. & Mart\u00ednez, M. A. Mathematical modelling of atheroma plaque formation and development in coronary arteries. J. R. Soc. Interface 11, 20130866 (2014).","journal-title":"J. R. Soc. Interface"},{"key":"1557_CR46","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1007\/s10439-019-02268-3","volume":"47","author":"NA Avgerinos","year":"2019","unstructured":"Avgerinos, N. A. & Neofytou, P. Mathematical Modelling and Simulation of Atherosclerosis Formation and Progress: A Review. Ann. Biomed. Eng. 47, 1764\u20131785 (2019).","journal-title":"Ann. Biomed. Eng."},{"key":"1557_CR47","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1051\/mmnp\/2019050","volume":"14","author":"NE Khatib","year":"2019","unstructured":"Khatib, N. E. et al. Mathematical modelling of atherosclerosis. Math. Model. Nat. Phenom. 14, 603 (2019).","journal-title":"Math. Model. Nat. Phenom."},{"key":"1557_CR48","doi-asserted-by":"crossref","unstructured":"Giugliano, R. P. et al. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke 51, 1546\u20131554 (2020).","DOI":"10.1161\/STROKEAHA.119.027759"},{"key":"1557_CR49","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1177\/2047487320902750","volume":"28","author":"P Sever","year":"2020","unstructured":"Sever, P. et al. LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. Eur. J. Prev. Cardiol. 28, 805\u2013812 (2020).","journal-title":"J. Prev. Cardiol."},{"key":"1557_CR50","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine, M. S. et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 5, 941\u2013950 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1557_CR51","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1001\/jamacardio.2017.3944","volume":"2","author":"RP Giugliano","year":"2017","unstructured":"Giugliano, R. P. et al. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. JAMA Cardiol. 2, 1385 (2017).","journal-title":"JAMA Cardiol."},{"key":"1557_CR52","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue, M. L. et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation 139, 1483\u20131492 (2019).","journal-title":"Circulation"},{"key":"1557_CR53","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jamacardio.2020.0882","volume":"5","author":"B Gencer","year":"2020","unstructured":"Gencer, B. et al. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction. JAMA Cardiol. 5, 952\u2013957 (2020).","journal-title":"JAMA Cardiol."},{"key":"1557_CR54","first-page":"8729003","volume":"2022","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis. Cardiol. Res. Pr. 2022, 8729003 (2022).","journal-title":"Cardiol. Res. Pr."},{"key":"1557_CR55","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jacbts.2016.08.007","volume":"1","author":"P Libby","year":"2016","unstructured":"Libby, P. Lipoprotein (a) A Frustrating Final Frontier in Lipid Management. JACC Basic Transl. Sci. 1, 428\u2013431 (2016).","journal-title":"JACC Basic Transl. Sci."},{"key":"1557_CR56","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-1-0716-3449-3_4","volume":"2716","author":"S Ars\u00e8ne","year":"2024","unstructured":"Ars\u00e8ne, S. et al. In Silico Clinical Trials: Is It Possible? Methods Mol. Biol. 2716, 51\u201399 (2024).","journal-title":"Methods Mol. Biol."},{"key":"1557_CR57","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/j.1528-1167.2011.03118.x","volume":"52","author":"J Bullman","year":"2011","unstructured":"Bullman, J. et al. Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. Epilepsia 52, 1351\u20131358 (2011).","journal-title":"Epilepsia"},{"key":"1557_CR58","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0149-2918(03)80214-X","volume":"25","author":"PD Martin","year":"2003","unstructured":"Martin, P. D., Warwick, M. J., Dane, A. L. & Cantarini, M. V. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin. Ther. 25, 2215\u20132224 (2003).","journal-title":"Clin. Ther."},{"key":"1557_CR59","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1185\/030079904125004213","volume":"20","author":"T Kosoglou","year":"2004","unstructured":"Kosoglou, T. et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr. Me\u0301d. Res. Opin. 20, 1185\u20131195 (2004).","journal-title":"Curr. Me\u0301d. Res. Opin."},{"key":"1557_CR60","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa, J. C. et al. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. N. Engl. J. Med. 352, 1425\u20131435 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1557_CR61","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","volume":"374","author":"S Yusuf","year":"2016","unstructured":"Yusuf, S. et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N. Engl. J. Med. 374, 2021\u20132031 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1557_CR62","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","volume":"107","author":"CM Ballantyne","year":"2003","unstructured":"Ballantyne, C. M. et al. Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia. Circulation 107, 2409\u20132415 (2003).","journal-title":"Circulation"},{"key":"1557_CR63","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1001\/jama.2014.4030","volume":"311","author":"JG Robinson","year":"2014","unstructured":"Robinson, J. G. et al. Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia: The LAPLACE-2 Randomized Clinical Trial. JAMA 311, 1870\u20131883 (2014).","journal-title":"JAMA"},{"key":"1557_CR64","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray, K. K. et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N. Engl. J. Med. 376, 1430\u20131440 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1557_CR65","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls, S. J. et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA 316, 2373 (2016).","journal-title":"JAMA"},{"key":"1557_CR66","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jcin.2009.04.016","volume":"2","author":"K Nasu","year":"2009","unstructured":"Nasu, K. et al. Effect of Fluvastatin on Progression of Coronary Atherosclerotic Plaque Evaluated by Virtual Histology Intravascular Ultrasound. JACC Cardiovasc. Interv. 2, 689\u2013696 (2009).","journal-title":"JACC Cardiovasc. Interv."},{"key":"1557_CR67","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.carrev.2016.11.010","volume":"18","author":"M Hougaard","year":"2017","unstructured":"Hougaard, M. et al. Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovasc. Revascularization Med. 18, 110\u2013117 (2017).","journal-title":"Cardiovasc. Revascularization Med."},{"key":"1557_CR68","doi-asserted-by":"publisher","first-page":"584.e1","DOI":"10.1016\/j.ahj.2007.11.018","volume":"155","author":"HR Underhill","year":"2008","unstructured":"Underhill, H. R. et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: A high-resolution magnetic resonance imaging trial. Am. Hear. J. 155, 584.e1\u2013584.e8 (2008).","journal-title":"Am. Hear. J."},{"key":"1557_CR69","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.atherosclerosis.2011.04.005","volume":"218","author":"AM West","year":"2011","unstructured":"West, A. M. et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis 218, 156\u2013162 (2011).","journal-title":"Atherosclerosis"},{"key":"1557_CR70","unstructured":"FDA. Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions. Guidance for Industry and Food and Drug Administration Staff. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/assessing-credibility-computational-modeling-and-simulation-medical-device-submissions (2023)."},{"key":"1557_CR71","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N. Engl. J. Med. 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1557_CR72","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12859-023-05430-w","volume":"24","author":"E Jacob","year":"2023","unstructured":"Jacob, E. et al. Empirical methods for the validation of time-to-event mathematical models taking into account uncertainty and variability: application to EGFR + lung adenocarcinoma. BMC Bioinform. 24, 331 (2023).","journal-title":"BMC Bioinform."},{"key":"1557_CR73","doi-asserted-by":"publisher","first-page":"e51607","DOI":"10.1371\/journal.pone.0051607","volume":"7","author":"Y-C Hwang","year":"2012","unstructured":"Hwang, Y.-C., Ahn, H.-Y., Lee, W. J., Park, C.-Y. & Park, S.-W. An Equation to Estimate the Concentration of Serum Apolipoprotein B. PLoS ONE 7, e51607 (2012).","journal-title":"PLoS ONE"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01557-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01557-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01557-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T07:32:39Z","timestamp":1742455959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-01557-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1557"],"URL":"https:\/\/doi.org\/10.1038\/s41746-025-01557-7","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A. reports having received payment or honoraria for lectures, presentations, speakers bureaus or educational events from Amgen, Alnylam, Amarin, Astra Zeneca, Boehringer, BMS, Bouchara Recordati, Pfizer, Novartis, Novo Nordisk, Organon, Sanofi, Servier, Vifor. P.A. reports: Grants: French government (PHRC: RIISC-THETIS, TST-40, SPICAF trials), Pfizer and AstraZeneca (TST trial); Speaker fee: Novartis, Viatris, Sanofi; Advisory board: Novartis, Neuraltide; Steering committee: Bayer. F.B. reports having received payments for consulting, speaking, or educational events from Amgen, Amarin, Novartis, Novo Nordisk, Boehringer, Servier, ViiV healthcare, Gilead and Sanofi. B.C. reports having received payments for consulting, speaking, or educational events from Amgen, Astra Zeneca, BMS, Eli Lilly, Novartis, Novo Nordisk, Sanofi, Ultragenyx. G.M. reports having received payments for consulting, speaking, or educational events from Amgen, Amarin, Bayer Healthcare, BMS, Leo Pharma, Novartis, Novo Nordisk, Pfizer and Sanofi. P.G.S. reports: Research grants: Amarin, Sanofi; Clinical Trials (Steering committee, CEC, DSMB): Amarin, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Idorsia, Janssen, Novartis, Novo-Nordisk, Pfizer, Sanofi; Consulting or speaking: Amarin, Amgen, BMS, Novo-Nordisk; Senior Associate Editor at Circulation; Chief Scientific Officer: Bioquantis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}